Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasimelteon safety extension in Non-24-Hour Sleep-Wake Disorder
NCT01429116Phase 3Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Oct 2011
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tasimelteon in Non-24-hour sleep-wake disorder (N24SWD), sponsored by Vanda Pharmaceuticals Inc.. Started Oct 2011; status: completed.
02
Drugs
tasimelteon
03
Conditions
Non-24-hour sleep-wake disorder (N24SWD)
Beyond the preview
Go deeper on NCT01429116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01429116.